Ceragenix Pharmaceuticals, Inc. Completes Long-Term Antimicrobial Efficacy Test on Treated Silicone Medical Device

DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) (the "Company"), a medical device company focused on infectious disease and dermatology, today provided an update on its previously disclosed, ongoing long-term preclinical testing of a silicone medical device incorporating the Company’s CeraShield™ antimicrobial technology. The prototype device being tested was an intravaginal silicone ring. Antimicrobial intravaginal rings may be of potential benefit in preventing transmission of certain sexually transmitted diseases. After 224 days of continuous antimicrobial efficacy, the coated ring lost its efficacy in preventing colonization and the test was ended.